Anti-osteoporosis drugs may be effective as COVID-19 prophyl
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In a study recently published in the journal Aging, a group of researchers in Spain indicated that some of the main drugs (denosumab, zoledronate and calcium) used for the treatment of non-inflammatory rheumatic conditions like osteoporosis, fibromyalgia and osteoarthritis, may be effective as prophylaxis for COVID-19.

The study was inspired by the fact that the specialists at the Hospital Del Mar, a general hospital in Spain, noted a low incidence of COVID-19 in osteoporosis patients.

The researchers included 2,102 volunteers with a mean age of 66.4 years in the study. Over 80% of the participants were women, about 63.7% had osteoarthritis, 43.5% had osteoporosis and 27.2% had fibromyalgia.

About 109 of the participants were confirmed to be COVID-19 positive between March and May 2020. These patients also had more comorbid conditions like diabetes, chronic kidney disease, cardiovascular disease and pulmonary disease as compared to those who did not test positive for COVID-19 .

They also had less exposure to drugs like denosumab, intravenous zoledronate, vitamin D and selective estrogen receptor modulators (SERMs) and higher exposure to antidepressants as compared to those who did not get the disease.

Based on the study, the researchers suggested that denosumab, zoledronate, calcium and the antidepressant duloxetine were negatively associated with COVID-19 incidence.

Specifically, the drugs were found to reduce the rate of infection by 30-40%. On the other hand, most other antidepressants and pain-relieving drugs, especially pregabalin, was positively associated with COVID-19 incidence.

As per the study, the drugs that were found to be effective had a different mechanism of action.

DENOSUMAB targets the RANK/RANKL system which reduces pro-inflammatory cytokines in the body and helps control inflammation, which is one of the major causes of life-threatening COVID-19.

ZOLEDRONATE reduces the susceptibility of certain immune system cells to SARS-CoV-2, which may explain the reduced incidence of COVID-19 in patients.

A possible mechanism, the researchers explained, through which it helps manage COVID-19 is the involvement of CALCIUM in the generation of T cells, a type of immune system cells responsible for fighting viruses.

Similarly, the antidepressant DULOXETINE helps balance T cells and cytokine production.

Dr. A●●●●●l S●●●●a and 2 other likes this7 shares